Firefly Hikes on Partnering with NeuroSigma
Firefly Neuroscience (AIFF) and NeuroSigma partnered to promote NeuroSigma's Monarch eTNS System, a non-drug ADHD treatment, through Firefly's Evoke platform network. AIFF shares rose 38.9% to $1.65. According to a 2024 study, 7.1 million U.S. children have ADHD, with many seeking non-medication treatments.
How this was made

The 30-second read
Why it matters
The collaboration could create a new revenue stream and enhance Firefly's market positioning in neuro‑tech.
Market read
First‑report partnership news with a sizable price jump suggests immediate trading opportunity.
What to watch
Regulatory timeline for broader FDA clearance of the Monarch system.
Background
Firefly Neuroscience provides AI‑powered EEG/ERP platforms; NeuroSigma's Monarch eTNS system is FDA‑cleared for pediatric ADHD.
Ticker impact
Firefly announced a strategic partnership with NeuroSigma, driving a 38.9% share jump to $1.65.
Further upside expected if partnership rollout accelerates.
First‑report partnership news with a large same‑day price move indicates strong market reaction.
Market effects
May boost the neuro‑tech and ADHD treatment sector as AI‑driven diagnostics gain traction.
U.S. biotech and med‑tech stocks could see modest lift.
Limited to companies focused on AI‑enabled neuro‑diagnostics.
Counterpoint
Partnership benefits may be overstated; execution risk could temper price gains.
Key entities
- companyFirefly Neuroscience, Inc.
AI‑driven neuro‑diagnostics firm (NASDAQ: AIFF).
- companyNeuroSigma, Inc.
Developer of the Monarch eTNS system for ADHD.





